FINWIRES · TerminalLIVE
FINWIRES

澳交所前瞻:受美伊谈判重启乐观情绪提振,澳股有望上涨;澳航上调2026财年燃油成本预期

-- 周二,澳大利亚股市有望上涨,此前由于中东紧张局势升级,石油市场受到冲击,美国正采取措施限制霍尔木兹海峡的航运。 美国总统特朗普表示,伊朗已主动联系美国,希望重启谈判。此前,周末在巴基斯坦伊斯兰堡举行的会谈以失败告终。投资者正在权衡全球能源供应进一步中断的风险。 隔夜,标普500指数、纳斯达克综合指数和道琼斯工业平均指数分别上涨1%、1.2%和0.6%。 澳大利亚联邦银行(ASX:CBA)周一发布的报告显示,在宏观经济方面,澳大利亚3月份季度工资增长0.8%,新增就业岗位约2.3万个,表明劳动力市场稳定但逐渐降温,工资增长已趋于稳定在一个新的基准线附近。 企业新闻方面,澳航(ASX:QAN)预计,由于2月份航空煤油炼油利润率达到每桶约120美元的峰值,其2026财年下半年的燃油成本将达到31亿至33亿澳元。 西太平洋银行(ASX:WBC,NZE:WBC)将提高对能源密集型行业客户的信贷拨备,原因是中东冲突造成的经济波动和不确定性。 澳大利亚基准股指周一下跌0.4%,或34.6点,收于8926点。

Related Articles

Asia

National Australia Bank Shares Down After Resolution of Union Court Proceedings

National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."

$ASX:NAB
Asia

Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant

Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.

$ASX:CUV
Asia

XRF Scientific Completes Acquisition of Combustion Gas Analysis Business

XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.

$ASX:XRF